Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

BACKGROUND: We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4(+)CD25(HI)Foxp3(+ )regulatory T cells and expanded melanoma-specific CD8(+ )T cells. The goal of this study was to asses...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Telang, Sucheta, Rasku, Mary Ann, Clem, Amy L, Carter, Karen, Klarer, Alden C, Badger, Wesley R, Milam, Rebecca A, Rai, Shesh N, Pan, Jianmin, Gragg, Hana, Clem, Brian F, McMasters, Kelly M, Miller, Donald M, Chesney, Jason
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2011
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3293785/
https://ncbi.nlm.nih.gov/pubmed/22165955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-515
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak